What is NTLA (NTLA) stock price today?

NTLA (NTLA) is currently trading at $12.69, down 0.35% today.

What is NTLA P/E ratio?

NTLA's P/E ratio is -3.55. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is NTLA return on equity (ROE)?

NTLA's return on equity (ROE) is -61.55%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is NTLA's market cap?

NTLA has a market capitalization of $1.77B.

NASDAQ · Biotechnology

NTLA (NTLA) Stock

$12.69 -0.35% NASDAQ: NTLA Healthcare

Valuation

Metric	Value
Price	$12.69
Market Cap	$1.77B
P/E Ratio	-3.55
P/B Ratio	2.26
P/S Ratio	21.54
EPS (TTM)	$-3.81
52-Week High	$28.25
52-Week Low	$7.95
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-61.55%
ROA	-49.05%
ROCE	-65.72%
Gross Margin	-648.53%
Operating Margin	-648.53%
Net Margin	-5.97%
Debt/Equity	0.13
Current Ratio	5.08

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$33.0M	$52.0M	$36.0M	$58.0M	$68.0M
Operating Profit	$-268.0M	$-458.0M	$-515.0M	$-534.0M	$-441.0M
Net Profit	$-268.0M	$-474.0M	$-481.0M	$-519.0M	$-413.0M
EPS	$-3.78	$-6.16	$-5.42	$-5.25	$-3.81
Op Margin	-810.4%	-879.0%	-1420.5%	-923.1%	-651.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.3B	$1.5B	$1.3B	$1.2B	$842.0M
Total Liabilities	$254.0M	$285.0M	$251.0M	$319.0M	$171.0M
Cash	$123.0M	$524.0M	$227.0M	$189.0M	$155.0M
Borrowings	$74.0M	$131.0M	$115.0M	$210.0M	$93.0M

Latest News

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success Simply Wall St. · Jul 9, 2026 NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? Zacks · Jul 9, 2026 Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns Simply Wall St. · Jul 9, 2026 Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears Barchart · Jul 8, 2026 A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics Motley Fool · Jul 8, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-225.0M	$-333.0M	$-394.0M	$-349.0M	$-349.0M
Investing Cash Flow	$-564.0M	$102.0M	$-45.0M	$120.0M	$120.0M
Financing Cash Flow	$43.0M	$17.0M	$11.0M	$9.0M	$54.0M
Net Cash Flow	$-39.0M	$410.0M	$-295.0M	$-38.0M	$-38.0M
Free Cash Flow	$-238.0M	$-392.0M	$-408.0M	$-355.0M	$-355.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-25.54%
Quick Ratio	6.10
Interest Coverage	—
Return 1Y	-22.05%
Return 3Y	-73.52%
Return 5Y	-90.37%

Ownership

Insiders Held3.88%

Institutions Held76.79%

Institutions Float Held79.89%

Institutional Holder	Shares	Report Date
ARK Investment Management, LLC	14,509,247	2026-03-31
Blackrock Inc.	12,155,806	2026-03-31
State Street Corporation	6,922,676	2026-03-31
Vanguard Portfolio Management LLC	6,223,325	2026-03-31
Shaw D.E. & Co., Inc.	5,728,177	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BCRX	$9.92	+2.27%	-6.83	$2.52B	0.00%
BHVN	$15.74	+3.08%	-6.11	$2.37B	0.00%
IMNM	$27.07	-1.26%	-8.13	$2.59B	0.00%
PHVS	$34.93	+0.92%	-9.75	$2.44B	0.00%
STOK	$30.89	-0.99%	-9.29	$1.99B	0.00%

About NTLA

NTLA is led by CEO John Leonard, employs 403 people, headquartered in US, publicly traded since 2016.

NTLA stock trades at $12.69 with a market capitalization of $1.77B. The stock is valued at a price-to-earnings (P/E) ratio of -3.55, price-to-book of 2.26, price-to-sales of 21.54. Over the past 52 weeks the stock has ranged between $7.95 and $28.25, and currently trades 55.1% below its 52-week high.

On profitability, NTLA generates a return on equity (ROE) of -61.55%, return on capital employed of -65.72%, an operating margin of -648.53%, a net profit margin of -5.97%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides